Lixte Biotechnology Holdings, Inc. – NASDAQ:LIXT
Lixte Biotechnology Holdings stock price today
Lixte Biotechnology Holdings stock price monthly change
Lixte Biotechnology Holdings stock price quarterly change
Lixte Biotechnology Holdings stock price yearly change
Lixte Biotechnology Holdings key metrics
Market Cap | 4.49M |
Enterprise value | N/A |
P/E | -2.13 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 2.61 |
PEG ratio | -0.10 |
EPS | -2.38 |
Revenue | N/A |
EBITDA | -4.68M |
Income | -4.69M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLixte Biotechnology Holdings stock price history
Lixte Biotechnology Holdings stock forecast
Lixte Biotechnology Holdings financial statements
| Jun 2023 | 0 | -1.66M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.01M | |
| Dec 2023 | 0 | -1.03M | |
| Mar 2024 | 0 | -971.32K |
| Jun 2023 | 3095148 | 402.61K | 13.01% |
|---|---|---|---|
| Sep 2023 | 5234696 | 311.73K | 5.96% |
| Dec 2023 | 4308620 | 313.85K | 7.28% |
| Mar 2024 | 3589203 | 462.83K | 12.9% |
| Jun 2023 | -1.17M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -944.38K | 0 | 3.13M |
| Dec 2023 | -902.12K | 3.13M | 0 |
| Mar 2024 | -789.22K | 0 | 0 |
Lixte Biotechnology Holdings alternative data
| Aug 2023 | 3 |
|---|---|
| Sep 2023 | 3 |
| Oct 2023 | 3 |
| Nov 2023 | 3 |
| Dec 2023 | 3 |
| Jan 2024 | 3 |
| Feb 2024 | 3 |
| Mar 2024 | 3 |
| Apr 2024 | 3 |
| May 2024 | 3 |
| Jun 2024 | 3 |
| Jul 2024 | 3 |
Lixte Biotechnology Holdings other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 82500 | 0 |
| Dec 2022 | 46112 | 0 |
| Oct 2023 | 25527 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BERNARDS RENE director | Common Stock | 5,527 | $2.51 | $13,873 | ||
Purchase | BERNARDS RENE director | Common Stock | 5,527 | $2.51 | $13,873 | ||
Purchase | VAN DER BAAN BASTIAAN JEROEN director, officer: President an.. | Common Stock | 10,000 | $2.8 | $28,000 | ||
Purchase | BERNARDS RENE director | Common Stock | 4,473 | $2.29 | $10,243 | ||
Purchase | VAN DER BAAN BASTIAAN JEROEN director | Common Stock | 20,000 | $2.7 | $53,900 | ||
Purchase | BERNARDS RENE director | Common Stock | 15,000 | $0.51 | $7,650 | ||
Purchase | BERNARDS RENE director | Common Stock | 10,000 | $0.61 | $6,100 | ||
Purchase | FORMAN ERIC officer: Vice Pre.. | Common Stock | 1,112 | $0.63 | $701 | ||
Purchase | FORMAN ERIC officer: Vice Pre.. | Common Stock | 2,484 | $0.56 | $1,391 | ||
Purchase | FORMAN ERIC officer: Vice Pre.. | Common Stock | 1,457 | $0.56 | $816 |
| Insider | Compensation |
|---|---|
Dr. James S. Miser M.D. (1948) Chief Medical Officer | $150,000 |
Mr. Robert Neal Weingarten (1952) Vice President & Chief Financial Officer | $119,980 |
| Dr. John S. Kovach (1937) Founder, Pres, Chief Executive Officer, Chief Scientific Officer & Chairman | $107,500 |
| Mr. Eric J. Forman J.D. (1980) Chief Admin. Officer | $64,890 |
-
What's the price of Lixte Biotechnology Holdings stock today?
One share of Lixte Biotechnology Holdings stock can currently be purchased for approximately $3.49.
-
When is Lixte Biotechnology Holdings's next earnings date?
Unfortunately, Lixte Biotechnology Holdings's (LIXT) next earnings date is currently unknown.
-
Does Lixte Biotechnology Holdings pay dividends?
No, Lixte Biotechnology Holdings does not pay dividends.
-
How much money does Lixte Biotechnology Holdings make?
Lixte Biotechnology Holdings has a market capitalization of 4.49M.
-
What is Lixte Biotechnology Holdings's stock symbol?
Lixte Biotechnology Holdings, Inc. is traded on the NASDAQ under the ticker symbol "LIXT".
-
What is Lixte Biotechnology Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lixte Biotechnology Holdings?
Shares of Lixte Biotechnology Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Lixte Biotechnology Holdings's key executives?
Lixte Biotechnology Holdings's management team includes the following people:
- Dr. James S. Miser M.D. Chief Medical Officer(age: 77, pay: $150,000)
- Mr. Robert Neal Weingarten Vice President & Chief Financial Officer(age: 73, pay: $119,980)
- Dr. John S. Kovach Founder, Pres, Chief Executive Officer, Chief Scientific Officer & Chairman(age: 88, pay: $107,500)
- Mr. Eric J. Forman J.D. Chief Admin. Officer(age: 45, pay: $64,890)
-
Is Lixte Biotechnology Holdings founder-led company?
Yes, Lixte Biotechnology Holdings is a company led by its founder Dr. John S. Kovach.
-
How many employees does Lixte Biotechnology Holdings have?
As Jul 2024, Lixte Biotechnology Holdings employs 3 workers.
-
When Lixte Biotechnology Holdings went public?
Lixte Biotechnology Holdings, Inc. is publicly traded company for more then 17 years since IPO on 25 Oct 2007.
-
What is Lixte Biotechnology Holdings's official website?
The official website for Lixte Biotechnology Holdings is lixte.com.
-
Where are Lixte Biotechnology Holdings's headquarters?
Lixte Biotechnology Holdings is headquartered at 680 East Colorado Boulevard, Pasadena, CA.
-
How can i contact Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings's mailing address is 680 East Colorado Boulevard, Pasadena, CA and company can be reached via phone at +63 18307092.
Lixte Biotechnology Holdings company profile:
Lixte Biotechnology Holdings, Inc.
lixte.comNASDAQ
3
Biotechnology
Healthcare
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Pasadena, CA 91101
CIK: 0001335105
ISIN: US5393193017
CUSIP: 539319202
